Last Updated: September 24, 2026

Details for New Drug Application (NDA): 022048

✉ Email this page to a colleague

NDA 022048 describes TRIESENCE, which is a drug marketed by Harrow Eye and is included in one NDA. It is available from two suppliers. There are two patents protecting this drug. Additional details are available on the TRIESENCE profile page.

The generic ingredient in TRIESENCE is triamcinolone acetonide. There is one drug master file entry for this compound. Eighty suppliers are listed for this compound. Additional details are available on the triamcinolone acetonide profile page.

Summary for 022048

Tradename:	TRIESENCE
Applicant:	Harrow Eye
Ingredient:	triamcinolone acetonide
Patents:	2

Pharmacology for NDA: 022048

Mechanism of Action	Corticosteroid Hormone Receptor Agonists

Medical Subject Heading (MeSH) Categories for 022048

Anti-Inflammatory Agents
Glucocorticoids
Immunosuppressive Agents

Suppliers and Packaging for NDA: 022048

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
TRIESENCE	triamcinolone acetonide	INJECTABLE;INTRAVITREAL	022048	NDA	Novartis Pharmaceuticals Corporation	0078-0897	0078-0897-78	1 BLISTER PACK in 1 CARTON (0078-0897-78) / 1 VIAL, GLASS in 1 BLISTER PACK / 1 mL in 1 VIAL, GLASS
TRIESENCE	triamcinolone acetonide	INJECTABLE;INTRAVITREAL	022048	NDA	Harrow Eye, LLC	82667-800	82667-800-01	1 BLISTER PACK in 1 CARTON (82667-800-01) / 1 VIAL, GLASS in 1 BLISTER PACK / 1 mL in 1 VIAL, GLASS

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	INJECTABLE;INTRAVITREAL			Strength	40MG/ML (40MG/ML)
Approval Date:	Nov 29, 2007	TE:		RLD:	Yes
Patent:	8,128,960	Patent Expiration:	Dec 17, 2029	Product Flag?	Y	Substance Flag?		Delist Request?
Patent:	8,211,880	Patent Expiration:	Mar 10, 2029	Product Flag?		Substance Flag?		Delist Request?
Patented Use:	TREATMENT OF OPHTHALMIC DISORDERS
Patent:	8,211,880	Patent Expiration:	Mar 10, 2029	Product Flag?		Substance Flag?		Delist Request?
Patented Use:	VISUALIZATION DURING VITRECTOMY PROCEDURES

Expired US Patents for NDA 022048

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Harrow Eye	TRIESENCE	triamcinolone acetonide	INJECTABLE;INTRAVITREAL	022048-001	Nov 29, 2007	6,395,294	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.